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Summary
Kappa opioid receptors (KORs) are involved in a variety of aversive behavioral states, including 
anxiety. To date, a circuit based mechanism for KOR driven anxiety has not been described. Here 
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we show that activation of KORs inhibits glutamate release from the basolateral amygdala (BLA) 
inputs to the bed nucleus of the stria terminalis (BNST), and occludes the anxiolytic phenotype 
seen with optogenetic activation of BLA-BNST projections. In addition, deletion of KORs from 
amygdala neurons results in an anxiolytic phenotype. Furthermore, we identified a frequency 
dependent optically-evoked local dynorphin-induced heterosynaptic plasticity of glutamate inputs 
in the BNST. We also find that there is cell type specificity to the KOR modulation of the BLA-
BNST input, with greater KOR-mediated inhibition of BLA dynorphin-expressing neurons. 
Collectively, these results provide support for a model in which local dynorphin release can inhibit 
an anxiolytic pathway, providing a discrete therapeutic target for treatment of anxiety disorders.
Graphical abstract
Introduction
Anxiety disorders are a major health concern, with 7.3% of the global population suffering 
from an anxiety disorder at any given time (Baxter et al., 2013; Lepine, 2002). Despite the 
high expense of anxiety disorder treatments (Lepine, 2002) many of the most common 
treatments, including tricyclic antidepressants, monoamine oxidase inhibitors, 
benzodiazepines, and selective serotonin reuptake inhibitors, have side effects that limit their 
utility (Ravindran, 2010). In light of these limitations, there has been a greater effort to 
discover new modulatory systems for the treatment of anxiety disorders (Deisseroth, 2014; 
Holden, 2003; Johansen, 2013; Tye et al., 2011). In order to develop new and more 
efficacious therapeutics, however, a more thorough understanding of the circuitry underlying 
anxiety disorders is required.
Kappa opioid receptors (KORs) have been proposed as a potential target for stress and 
anxiety disorders, as well as substance abuse disorders (Wee and Koob, 2010). An 
abundance of behavioral pharmacological experiments have shown an anxiolytic effect of 
KOR antagonists are capable of overcoming the anxiogenic effects of a chronic or acute 
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stressor, ethanol withdrawal, CRF, and KOR agonism (Bruchas et al., 2009; Knoll et al., 
2007; Valdez and Harshberger, 2012). Findings have implicated recruitment of KOR 
signaling by its endogenous ligand dynorphin (Chavkin et al., 1982) as playing a key role in 
preclinical and clinical models of anxiety (Knoll et al., 2011); however the mechanism that 
underlies this effect and the circuitry involved has not yet been defined(Crowley and Kash, 
2015). KOR modulation has been identified in key anxiety-related regions such as the dorsal 
raphe nucleus (Bruchas et al., 2010; Land et al., 2009), the ventral tegmental area (Spanagel 
et al., 1992), and the prefrontal cortex (Svingos and Colago, 2002; Tejeda et al., 2013). 
These regions interact with the bed nucleus of the stria terminalis (BNST), a key region 
involved in anxiety-related behaviors (Kash, 2012); however, thus far investigation of KORs 
in the BNST has so far been lacking. In addition, the BNST is known to express 
preprodynorphin (Poulin et al., 2009), and previous work from our lab has demonstrated 
KOR modulation of GABAergic transmission in the BNST (Li et al., 2012a). Together, these 
studies support the idea that KORs in the BNST could be a promising and important target 
for neuropsychiatric manipulations.
Based on the abundance of evidence implicating KORs in anxiety disorders, and the known 
role of the BNST in regulating anxiety-like behavior, we evaluated the role of KOR 
modulation of glutamate transmission in the BNST. We also examined the ability of local 
BNST dynorphin neurons to heterosynaptically modulate glutamatergic transmission. Here, 
we report that KORs in the BNST inhibit glutamatergic transmission on the BLA but not the 
PFC inputs. We also demonstrate alterations in anxiety-related behaviors through 
complementary manipulations of KORs and this circuit. Furthermore, we identify a 
technological approach to assessing peptidergic transmission in slice.
Materials and Methods
Subjects
All animal procedures were performed in accordance with the Institutional Animal Care and 
Use Committee at the University of North Carolina at Chapel Hill and the Animal Care and 
Use Committee of Washington University, conforming to US National Institutes of Health 
guidelines. Experiments were performed on adult male C57BL/6J mice and DBA/2J mice, 
both from Jackson Laboratory (Bar Harbor, ME). In addition, Preprodynorphin-IRES-Cre 
and R26-loxSTOPlox-L10-GFP (Al-Hasani et al., 2015; Krashes et al., 2014), and Floxed 
KOR conditional knock-out mice (Chefer et al., 2013) were generated as described 
previously, and bred in house at UNC. All mice were group housed in colony rooms with a 
12:12hr light-dark cycle (lights on at 7 a.m.) with ad libitum access to rodent chow and 
water.
Slice electrophysiology
Coronal sections containing the BNST (300μM) were obtained from behaviorally-naïve 
mice rapidly decapitated under isoflurane. All experiments were conducted in the 
dorsolateral portion of the BNST. Lidocaine N-ethyl bromide (1 mg/ml) was included in the 
intracellular recording solution to prevent postsynaptic sodium spikes for all voltage-clamp 
experiments. For basal KOR pharmacological effects and characterization, picrotoxin (25 
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μM) was added to aCSF to isolate excitatory postsynaptic currents (EPSCs). Tetrodoxtoin 
(500nM) and picrotoxin (25μM) were added to the aCSF to isolate miniature EPSCs. Cells 
were held at -70mV to isolate AMPAR-mediated current (see the Supplemental 
Experimental Procedures).
For ex vivo optogenetic experiments, all brains were evaluated for light-evoked action 
potentials in the injection region (BLA, PFC, PVN, or BNST) using a potassium-gluconate-
based internal recording solution. Brains were discarded and not used for further 
experimentation if action potentials were not obtained or injection sites were missed. A blue 
LED (470nm, CoolLed, Hampshire, United Kingdom) was used to optically stimulate 
release from channelrhodopsin (ChR2)-containing fibers (5 msec pulse for voltage-clamp 
experiments, 1 msec for current clamp experiments).
Stereotaxic surgery
Male mice were injected with viral constructs into regions of interest. A craniotomy was 
performed, and mice were bilaterally injected using a blunt needle (86200 and 65458-01, 
Hamilton Company, Reno, NV), with 400-500 nl of the vector into the BLA (stereotaxic 
coordinates from bregma: -1.30 anterior-posterior, +/−3.15 medial-lateral,–4.95 mm dorsal-
ventral), 350 nl of the vector into the BNST (stereotaxic coordinates from bregma: +0.27 
anterior-posterior, +/-0.90 medial-lateral, -4.25 dorsal-ventral), or 400-500 nl of the vector 
into the PFC (stereotaxic coordinates from bregma: +1.8 anterior-posterior, +/- 0.3-0.5 
medial-lateral, -2.5 dorsal-ventral). For floxed KOR slice electrophysiology experiments, 
ChR2/CRE cocktail was prepared (250nL ChR2, 250nL CRE) and injected into the BLA.
Mice were allowed to recover for at least six weeks prior to behavioral experiments or 
electrophysiology (see the Supplemental Experimental Procedures).
Behavior
Anxiety-related behavioral assays were conducted as described previously (Pleil et al., 
2015). Briefly, in the first series of experiments, floxed KOR knock-out mice with either 
ChR2-eYFP or Cre-GFP injected in the BLA were placed in the elevated plus maze for five 
minutes. For these experiments, a virus encoding ChR2 was injected in to control mice, but 
no in vivo illumination was used. In the second series of experiments, mice with either 
ChR2-eYFP or eYFP injected in the BLA with optical fibers in the BNST were systemically 
administered either saline or a KOR agonist. Thirty minutes later, they were tested in the 
open field.
Elevated Plus Maze
The elevated plus maze (EPM; Med Associates, St. Albans, VT) was made of white and 
black plastic and consisted of two open arms (75 × 7 cm) and two closed arms (75 × 7 × 25 
cm) adjoined by a central area (7 × 7 × 25 cm). The arms were arranged in a plus 
configuration with arms of the same type (open or closed) opposite of each other. The maze 
was elevated 75cm with light levels maintained at 15 lux throughout the experiment. Mice 
were placed in the center of the EPM and allowed to explore freely. The EPM was cleaned 
with 70% ethanol between each trial. Movements were video recorded and analyzed using 
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Ethovision 9.0 (Noldus Information Technologies, Leesburg, VA). The primary measures of 
reduced anxiety-like behavior were time spent in the open arm and number of entries into 
the open arm.
Open Field Test
Mice were injected with the KOR agonist U50,488 (5 mg/kg in saline, i.p.) or vehicle 
control (saline) and returned to their home cage for 30 min. The open field test was 
performed in a square enclosure (55 × 55 cm) with light levels maintained at 25 lux. Mice 
were placed in the center of the open field and allowed to roam freely for 21 min. 
Photostimulation alternated between off and on states in 3 min time segments, beginning 
with 3 min of no stimulation. For the photostimulated time segments, animals received 10 
Hz (10 ms width) photostimulation (∼10 mW light power). The open field was cleaned with 
70% ethanol between each trial. Movements were video recorded and analyzed using 
Ethovision 8.5 (Noldus Information Technologies, Leesburg, VA). The center was defined as 
a square comprised of 50% the total area of the OFT. Time in the center was the primary 
measure of anxiety-like behaviors.
Histological verification
Nissl staining was performed in cohorts of mice used for in vivo optogenetics to confirm 
injections and fiber placements (see the Supplemental Experimental Procedures).
Viral vectors
The viral constructs AAV2-CaMKIIα-ChR2-eYFP, AAV2-CaMKIIα-eYFP, AAV5-EF1α-
DIO-ChR2-eYFP, AAV5-EF1α-DIO-eYFP, AAV5-EF1α-DIO-ChR2-mCherry, AAV5-
CaMKIIα-ChR2-eYFP, AAV5-CaMKIIα-Cre-GFP, and AAV2-CaMKIIα-Cre-eYFP, 
described elsewhere (Kim et al., 2013) were obtained from the UNC Viral Vector Core 
(Chapel Hill, NC).
Data analysis and statistics
Data are expressed as means ± SEM for all figures. For all experiments, 2-way ANOVAs, 
paired t-tests, unpaired t-tests, and linear regression were used where appropriate, as 
described in figure captions. Statistical analyses were conducted using Prism 6.0 (GraphPad, 
La Jolla, CA), and figures were made in Illustrator CC 2015 (Adobe, San Jose, CA).
Results
KORs signal via a presynaptic, p38- and calcium-dependent mechanism to inhibit 
glutamate release in the BNST
An extensive body of literature links glutamate signaling in the BNST to both anxiolytic and 
anxiogenic behavior (Davis et al., 2010; Hubert and Muly, 2014; Kim et al., 2013). 
Therefore, we first examined whether KOR activation could alter glutamate function in the 
BNST. We found that multiple KOR-selective agonists (Dynorphin-A and U69,593) 
inhibited electrically-evoked excitatory post synaptic currents (eEPSCs) in the BNST, both 
of which were blocked by pre-application of the selective KOR antagonist norBNI (Figure 
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1A-D). This KOR-mediated inhibition was not reversed by norBNI (Figure 1E-F), 
suggesting that this is a form of long lasting plasticity. We next assessed the intracellular 
signaling mechanism of this KOR modulation, as KORs have been shown to signal through 
both p38 (Bruchas et al., 2007) and MEK/ERK (Li et al., 2012a). p38 signaling in particular 
has been shown to be necessary for the dysphoria associated with KOR activation (Bruchas 
et al., 2007). The KOR agonist effect was blocked in the presence of the p38 inhibitor 
SB203580 but not the MEK/ERK inhibitor SL-327 (Figure 1G) or the PKA inhibitor RP-
Camps (Figure 1H). Together, these results suggest that KOR mediated inhibition of 
glutamate function in the BNST involves p38, but not ERK or PKA signaling.
We next determined the impact of KOR agonists on miniature excitatory synaptic 
transmission to more clearly understand the mechanism of inhibition. KOR activation 
reduced miniature EPSC frequency but not amplitude, with no alterations in miniature EPSC 
kinetics (Figure 1I-K). This KOR modulation of mEPSCs was absent when recordings were 
conducted in zero calcium conditions similar to those previously published (Figure 1L-M). 
Taken together, this demonstrates a presynaptic, p38- and calcium-dependent form of 
glutamate inhibition, mechanistically similar to a form of long-term depression (LTD) that 
has been seen in the dorsal striatum following activation of opioid receptors (Atwood et al., 
2014).
KORs inhibit pathway-specific glutamate inputs to the BNST
Glutamatergic innervation to the BNST arises from multiple cortical and subcortical nuclei 
(Dong et al., 2001; Kim et al., 2013). We next probed KOR inhibition of two of these 
pathways, the prefrontal cortex (PFC) and the basolateral amygdala (BLA). We injected 
ChR2 (AAV2-CaMKIIα-ChR2-eYFP) in either the BLA or PFC and conducted slice 
electrophysiology experiments in the BNST. Independent activation of these pathways 
produced a robust, light-evoked EPSC, consistent with other studies examining BLA 
projections (Felix-Ortiz et al., 2013) (Figure 2A-C). The light-evoked BLA-BNST EPSC 
was inhibited by KOR activation, while the light-evoked PFC-BNST EPSC not altered by 
KOR agonist (Figure 2D), demonstrating that KOR modulation of glutamate transmission is 
pathway specific. Optogenetic activation of the BLA input to the BNST produced action 
potentials in BNST neurons reliably up to 20-40 hz (Figure 2E). As we have previously 
shown that KOR activation can inhibit GABA release (Li et al., 2012b), we wanted to test 
whether activation of KOR signaling would lead to a net reduction of BLA-induced action 
potentials in the BNST. Consistent with a net inhibitory action of KOR on this pathway, the 
KOR agonist significantly reduced the fidelity of these BLA-BNST induced action 
potentials. This demonstrates that presynaptic KORs show specificity in inhibition of 
glutamate inputs in the BNST.
KORs are expressed presynaptically, and modulate BLA-BNST anxiety-related behaviors
We next investigated the role of KOR in this pathway in vivo and ex vivo using a genetic 
approach. We injected AAV5-CaMKIIα-Cre-GFP (Cre) or AAV5-CaMKIIα-ChR2-eYFP 
(Control) into the BLA of conditional KOR knockout mice (Chefer et al., 2015) and 
assessed changes in anxiety-related behavior (Figure 3A-C). Viral deletion of KORs 
expressed on amygdala neurons resulted in an increase in EPM open arm time (Figure 3C) 
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with no alteration in total distance traveled (Figure 3D). In these experiments, there was 
expression of the cre virus in both the CeA and adjacent cortex in subsets of animals; 
however, the expression in these regions did not correlate to any behavioral measures. In 
order to confirm the presynaptic locus of KOR modulation at BLA-BNST synapses in vitro, 
we injected a cocktail of CaMKIIα-ChR2-eYFP and CaMKIIα-Cre-GFP into the BLA of 
KOR KO mice. This approach deletes KORs expressed on amygdalar neurons, while 
simultaneously allowing us to optogenetically activate this specific circuit in slice 
electrophysiology experiments. KOR-mediated inhibition of the BLA input was absent when 
KORs were genetically deleted from the BLA (Figure 3E). Together, this confirms that 
KORs are expressed presynaptically on BLA neurons, and demonstrates that deletion of 
amygdala KORs results in an anxiolytic phenotype.
In order to further understand the role of BNST KORs in anxiety-related behavior, we next 
probed this system using in vivo optogenetics (Figure 3F). Optogenetic activation of the 
BLA-BNST pathway produced a robust anxiolytic effect in the open field, replicating the 
effects found by others (Kim et al., 2013). Following administration of a sub-anxiogenic 
dose of the KOR agonist U50,488 (5mg/kg i.p.), activation of the BLA-BNST-induced 
anxiolytic phenotype, as well as locomotor behavior, was reduced as compared to control 
mice (Figure 3G-I). Together, these complementary behavioral approaches demonstrate that, 
globally, KORs are an important regulator of the BLA-BNST anxiety circuit, and that BLA 
KORs are critically involved in anxiogenic behavior.
Dynorphin is a heterosynaptic messenger in the BNST, and dynorphin neurons are 
preferentially modulated by KORs on BLA to BNST synapses
Finally, we assessed the capacity of dynorphin neurons in the BNST to release dynorphin 
following optogenetic stimulation. We stereotaxically injected ChR2 using a Cre-dependent 
vector (AAV5-EF1α-DIO-ChR2-EYFP) in the BNST of Preprodynorphin-IRES-Cre mice 
(Al-Hasani et al., 2015; Krashes et al., 2014). Dynorphin-positive (DYN+) neurons were 
located throughout the dorsal-lateral BNST (Figure 4A). Light activation of these cells 
reliably produced action potentials at up to 20 Hz and resulted in a monosynaptic IPSC 
(mean = 422.9, SEM = 149.0), but no EPSC (mean = -17.64, SEM = 6.414) (Figure 4B) 
onto neighboring, putatively non-dynorphin (DYN-) neurons, indicating BNST DYN+ 
neurons form robust local synapses that are exclusively GABAergic. We next probed 
whether optogenetic activation of these DYN+ neurons was capable of altering electrically-
evoked glutamate release within the BNST. 5 hz activation of DYN+ neurons for 150 
seconds produced a transient norBNI-sensitive (KOR-mediated) inhibition of eEPSCs 
(Figure 4C), however the EPSC amplitude returned to baseline within minutes. 20 hz 
stimulation for 150 seconds produced a robust and lasting inhibition of eEPSCs (Figure 4D); 
this inhibition was blocked by pre-application of the selective KOR antagonist norBNI. This 
effect was indistinguishable from that seen with KOR agonist application (Figure 1A-D). 
This effect was not seen when an identical approach was performed assessing a GABAergic 
dynorphin projection to the BNST from the paraventricular nucleus of the hypothalamus 
(PVN) (Figure 4E). 20 hz activation of PVN-BNST dynorphin neurons did produce an 
inhibition of eEPSCs, but this inhibition was not KOR-dependent, suggesting that another 
modulatory system may be playing a role in this distal inhibition by dynorphin neurons 
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(Bodnar, 2013). Taken together, these experiments demonstrate that activation of local 
BNST dynorphin neurons can inhibit electrically-evoked glutamatergic transmission in the 
BNST. Additionally, these experiments suggest a possible timing-dependent component in 
the persistence of KOR plasticity, similar to what has been demonstrated with 
norepinephrine-induced LTD in the BNST (McElligott and Winder, 2008).
We next assessed the relationship between BLA inputs to the BNST and BNST dynorphin 
neurons. In order to assess the BLA inputs onto DYN+ and DYN- neurons separately, ChR2 
(AAV2-CaMKIIα-ChR2-eYFP) was injected into the BLA and a cre-dependent fluorophore 
(AAV5-EF1α-DIO-mCherry) was injected into the BNST of Preprodynorphin-IRES-Cre 
mice (Figure 4F). DYN+ neurons had smaller membrane resistance than their DYN- 
counterparts, and a trend towards significant differences in cell capacitance (Supplementary 
Figure 1A-B), consistent with known classifications of BNST neuron types (Hammack et 
al., 2007). DYN- neurons had more action potentials per current injection when held at 
RMP, indicative of greater intrinsic excitability (Supplementary Figure 1C-K). Both DYN+ 
and DYN- neurons received a glutamate projection from the BLA, as well as a polysynaptic 
GABAergic projection, but no basal differences were seen with BLA innervation of these 
cells as indicated by similar paired pulse ratio and amplitude of evoked responses 
(Supplementary Figure 2A-D). We next examined KOR modulation of BLA inputs to these 
two discrete cell types. We found that KOR activation more robustly inhibited BLA-induced 
eEPSCs in DYN+ neurons as compared to DYN- neurons (Figure 2G). Taken together, these 
data suggest that there is both pathway- and cell- type dependent modulation of glutamate 
function in the BNST by KOR, allowing for important gating of glutamate transmission at 
DYN+ and DYN- neurons.
Discussion
The BNST has been shown to orchestrate both rewarding and aversive behaviors (Jennings 
et al., 2013; Kim et al., 2013). KORs have historically been thought to modulate aversive (or 
negatively regulate rewarding) systems (Chefer et al., 2005) or anxiety related behaviors, 
though recent literature has shown that that the neuroanatomical location of KORs may be 
important in behavioral effects seen with their activation. Castro and Berridge (2014) 
demonstrated that activation of KORs in the nucleus accumbens can mediate both 
conditioned place preference and conditioned place aversion. This work was expanded 
recently expanded upon when Al-Hasani et al. (2015) demonstrated that activation of DYN+ 
neurons themselves in distinct subpopulations of the nucleus accumbens is responsible for 
rewarding or aversive behavioral phenotypes, and found that photo-activation of the aversive 
subpopulation of accumbens dynorphin neurons did not results in anxiogenic behavior. The 
diversity in effects seen with KOR activation, coupled with the multitude of behavioral 
outcomes seen with the BNST activation in this study, places KORs in the BNST at the 
interesting and likely position of being able to modulate anxiety-related behaviors. 
Furthermore, these results suggest that KORs are poised to regulate negative affective 
behavioral states (aversion) and anxiety via discrete brain subnuclei.
We demonstrate that KOR activation in the BNST inhibits glutamatergic inputs by a 
presynaptic, p38-, and calcium- dependent mechanism. Previous work has shown p38-
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dependent effects of KOR modulation in other brain regions, such as the dorsal raphe 
nucleus (Bruchas et al., 2011; Land et al., 2008; Lemos et al., 2012), and others have 
postulated that this intracellular signaling pathway may be critical for the dysphoric effects 
of KOR agonists (Bruchas et al., 2007). In addition, previous work by our lab demonstrated 
that KORs inhibit BNST GABAergic transmission via MEK/ERK signaling (Li et al., 
2012a). We therefore show that KORs within the BNST are capable of altering 
neurotransmitter transmission via pharmacologically distinct mechanisms at different 
synapses. Differential use of signaling pathways by KORs has been demonstrated in the 
nucleus accumbens (Hjelmstad and Fields, 2003), and these pharmacologically distinct 
signaling mechanisms may play a key role in the development of functionally biased 
compounds. Development or identification of biased ligands, capable of targeting individual 
signaling pathways, may be useful in developing therapeutic treatments without the 
unpleasant side-effects seen with KOR activation (White et al., 2014).
Beyond a pharmacologically distinct mechanism of KOR inhibition, we also demonstrate a 
pathway-specific inhibition of glutamatergic inputs to the BNST. KORs inhibit BLA but not 
PFC inputs to the BNST; this mechanism may provide for gating of information flow both to 
and from the BNST. Future work should address other inputs to the BNST, including the 
multitude of inputs recently identified in the human brain (Avery et al., 2014). We also 
demonstrate a mechanism by which KORs are activated: GABAergic/dynorphin co-
expressing neurons in the BNST release dynorphin to presynaptically inhibit glutamate 
inputs to the BNST. This signaling mechanism through which dynorphin regulates 
transmission may be a common motif throughout the brain: it was originally postulated to be 
the mechanism of inhibition in the hippocampus (Drake et al., 1994), and, more recently, 
was shown to be the mechanism of inhibition in the PVN (Iremonger and Bains, 2009). We 
not only show similar findings in the BNST, but we expand upon this literature by 
demonstrating an optogenetic mechanism for activation of such release. This allows for 
peptidergic and optogenetic coupling, greatly expanding upon the ability to assess peptide 
release both in vitro and in vivo.
In addition, we used complementary approaches to identify behavioral changes in anxiety-
related behaviors following manipulations of the KOR system. When KORs were 
genetically deleted from BLA neurons using a viral cre approach coupled with the floxed 
KOR mouse, we saw a decrease in anxiety-related behavior in the EPM. Though other 
projections such as those to the CeA and hippocampus are likely also important pathways in 
this phenotype, the BLA-BNST has been previously demonstrated to be involved in anxiety-
like behavior and the EPM (Kim et al., 2013). Therefore, KORs are likely to be a key 
regulator of this pathway and phenotype. In a complementary series of experiments, we 
demonstrated in vivo activation of BLA-BNST neurons produced a robust anxiolytic 
phenotype (replicating work by Kim et al.). Importantly, systemic activation of KORs 
occludes the anxiolytic effect seen with BLA-BNST activation; though optogenetic 
activation of the BLA-BNST pathway can produce a robust anxiolytic phenotype, this 
pathway is gated by the dynorphin/KOR system.
Importantly, we found this KOR inhibition exhibited both cell-type and pathway-dependent 
differences in function. Though BLA inputs to the BNST show similar properties onto both 
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DYN+ and DYN- neurons, there is a greater KOR-mediated inhibition of BLA-DYN+ 
synapses versus BLA-DYN- synapses. These results suggest a model in which activation of 
the BNST by the BLA excites DYN+ neurons, and this activation leads to a local retrograde 
release of dynorphin. This dynorphin release then gates inputs to the BNST, potentially 
providing a homeostatic balance within the system during times of heightened activity, 
suggesting a mechanism by which KOR antagonists exhibit anxiolytic actions. In addition, 
this further illuminates the micro-circuitry of the BNST and how it may coordinate such a 
broad range of behavioral states, such as those involved in stress and addiction. Further, this 
raises a strategy for development of anxiolytic compounds—blocking endogenous inhibitors 
of defined circuits that reduce anxiety.
Further work is necessary to elucidate the downstream effects of BNST dynorphin neurons. 
Specifically, an understanding is needed of their projection and activation patterns, this is 
especially important in light of several recent findings detailing various sub-domains in the 
BNST that are linked with specific behaviors. This work provides an important framework 
to begin that research: though the circuitry of DYN+ and DYN-neurons may be equal, their 
activation and inhibition may not be. Taken together, this work demonstrates a pathway 
specific, p38- and calcium- dependent form of KOR inhibition of glutamate. It also 
demonstrates a mechanism by which local dynorphin release may mediate this presynaptic 
effect. Finally, this work shows that KORs may preferentially inhibit glutamatergic inputs 
onto DYN+ neurons, versus DYN- neurons, allowing for specific gating of information flow. 
This circuit-based approach has numerous advantages over existing approaches, as it allows 
higher precision in defining the substrate and mechanism of action. Given the lack of 
efficacious and well-tolerated anxiolytic medications currently available, this work 
introduces a site-specific manipulation of the mammalian anxiety system.
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Highlights
• KORs presynaptically inhibit BLA glutamate transmission in the BNST
• Optogenentic activation of local dynorphin neurons produces inhibition of 
glutamate
• Deletion of amygdala KORs produces an anxiolytic phenotype in the elevated 
plus maze
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Figure 1. KOR activation inhibits glutamate transmission in the BNST
(A) Representative experiment demonstrating KOR-mediated inhibition of eEPSC 
amplitude. Inset, eEPSC trace from the same neuron showing pre (black) and post (red) 1μM 
U69,593 application. Scale bar represents 200pA by 20msec. (B) KOR activation by 
U69,593 inhibited eEPSC amplitude (red circles, paired t-test, baseline v. min 21-25, t4 = 
30.70, P < 0.001) and was blocked by continuous application of the KOR antagonist 
norBNI, 100nM (yellow circles, paired t-test, baseline v. min 21-25, t4 = 0.003, P > 0.05); 
the KOR agonist U69,593 significantly inhibited eEPSC amplitude as compared to the 
norBNI block effect (unpaired t-test, acsf v. norBNI, min 16-20, t8 = 10.22, P < 0.001). (C) 
Representative experiment demonstrating KOR inhibition by 300nM Dynorphin-A. (D) 
KOR activation by 300nM Dynorphin-A produces a robust inhibition of eEPSCs (red 
circles, paired t-test, baseline v. min 21-25, t4 = 18.65, P < 0.001) that is blocked by the 
KOR antagonist norBNI (yellow circles, paired t-test, baseline v. min 21-25, t4 = 2.783, P = 
0.05) mimicking the results seen with U69,593 (Fig. 1B). Both U69,593 (E) and Dynorphin-
A (F) activation of KORs are non-reversible forms of inhibition. Post U69,593 application of 
the KOR antagonist norBNI (100nm) failed to reverse the inhibition by either KOR agonist 
(U69,593, paired t-test, baseline v. min 21-25, t4 = 13.88, P < 0.001; Dynorphin-A, paired t-
test, baseline v. min 21-25, t4 = 14.30, P < 0.001). (G) The p38 inhibitor SB203580 (10μM) 
but not the MEK/ERK inhibitor SL-327 (20μM) blocked KOR-mediated inhibition of 
eEPSCs (SB203580 effect, baseline v. min 16-20, t4 = 2.619, P > 0.05; SL-327 effect, 
baseline v. min 16-20, t4 = 14, P < 0.0001). (H) The PKA inhibitor RpCamps (5μM) does 
not alter eEPSCs (paired t-test, baseline v. min 16-20, t4 = 10, P = 0.0004) (I) Representative 
mEPSC traces (top and bottom) pre (left) and post (right) U69,593 application, conducted in 
500nM TTX and 5μM picrotoxin. No significant changes in mEPSC decay kinetics were 
seen, (not shown, paired t-test, t6 = 0.8170, P > 0.1). (J) mEPSC frequency (paired t-test, t5 
= 5.567, P < 0.001) but not amplitude (K) (paired t-test, t5 = 0.2141, P > 0.1) was reduced 
following application of the KOR agonist U69,593 Raw values for mEPSC frequency (not 
shown, baseline frequency mean = 3.406, SEM = 3.475; post-U69,593 frequency mean = 
2.179, SEM = 1.118) and amplitude (not shown, baseline amplitude mean = -29.36, SEM = 
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1.944, post-U69,593 amplitude mean = -25.71, SEM = 1.465). This inhibition is abolished in 
zero calcium aCSF, where both frequency (L) (paired t-test, t5 = 1.959, P > 0.05) and 
amplitude (M) (paired t-test, t5 = 2.017 P > 0.05) of mEPSCs remain unaltered by U69,593.
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Figure 2. KOR-mediated inhibition of eEPSCs is pathway specific
(A) Left, representative injections of ChR2 to the BLA and expression in the BNST. Right, 
representative traces for light-evoked EPSCs from the BLA (top, blue) and PFC (bottom, 
green). (B) Both the PFC and BLA send robust glutamatergic projections to the BNST, 
which do not differ in amplitude (unpaired t-test, t8 = 1.901, P > 0.05). (C) The BLA sends a 
monosynaptic EPSC and significantly time-delayed polysynaptic IPSC (paired t-test, t7 = 
5.232, P < 0.01), comparable to BLA projections to other outputs. (D) Similarly, the PFC 
sends a monosynaptic EPSC and a significantly time-delayed polysynaptic IPSC (paired t-
test, t4 = 4.138, P < 0.05). (E) KOR activation inhibits BLA-BNST light-evoked EPSC 
amplitude (paired t-test, baseline v. min 16-20, t4 = 14.86, P < 0.0001). However, KOR 
application did not alter PFC-BNST light-evoked EPSC transmission (paired t-test, baseline 
v. min 16-20, t4 = 0.6899, P > 0.1) (F) U69,593 reduces the fidelity of light-evoked BLA-
BNST action potentials. When fitted with standard linear regression, the slope was 
significantly non-zero predrug application (F1,28 = 12.86, P < 0.01) but not post (F1,28 = 
2.472, P > 0.05). The lines also showed significant different intercept points (F1,57 = 5.51, P 
< 0.05). Inset, representative traces of action potential fidelity at 20hz 5msec light 
stimulation pre (dark blue) and post (light blue) U69,593 application. Black boxes indicate 
light pulses.
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Figure 3. Deletion of KORs from amygdala neurons increases anxiolytic behavior in the EPM 
and blocks KOR agonist induced reduction of BLA to BNST inputs, while systemic activation of 
KORs occludes BLA-BNST driven anxiolytic behavior in the open field
(A) Top, outline of experimental procedure. Floxed KOR mice were injected with either 
Control or Cre (behavior) or a cocktail of ChR2 and Cre (electrophysiology) bilaterally to 
the BLA. Following ample time for virus to express, experiments were conducted. Bottom, 
representative injection of Cre-GFP into the BLA of floxed KOR mice. (B) Representative 
heatmaps for Control (left) or Cre (right) mice. Enclosed arms are horizontal and open arms 
are vertical. Scale bar represents intensity of behavior. (C) Cre mice showed significantly 
greater open arm time compared to Control mice (unpaired t-test, Cre v. ChR2, t14 = 2.215, 
P < 0.05). (D) No differences in total distance traveled were seen (unpaired t-test, Cre- v. 
ChR2, t14 = 0.4226, P > 0.05). (E) Deletion of KORs from BLA neurons prevented the 
KOR-mediated inhibition of BLA-BNST synapses, confirming that KORs act pre-
synaptically to inhibit evoked glutamate release. Mice were injected with ChR2 (AAV2- 
CaMKIIα-ChR2-eYFP) and Cre (AAV2-CaMKII-Cre-GFP) into the BLA, and light-evoked 
EPSCs were recorded in the BNST. U69,593 no longer inhibited light-evoked EPSCs (paired 
t-test, baseline v. min. 16-20, t4 = 1.474, P > 0.1). (F) Top, outline of experimental 
procedure. C57 mice were injected with either ChR2 or eYFP unilaterally to the BLA, and 
optical fibers were implanted above the BNST. Following ample time for virus to express, 
experiments were conducted. Bottom, representative injection of ChR2 into the BLA, and 
fiber placement in the BNST. Scale bar represents 100 μM. (G) A 2-way ANOVA revealed a 
significant effect of drug (F1,31=22.28, P < 0.001) as well as an interaction between drug and 
ChR2 (F1,31=5.210, P < 0.05) on number of entries into the center of the open field. Tukey's 
multiple comparisons showed a significant decrease of entries into the center in ChR2-U50 
mice as compared to ChR2-Saline mice (P < 0.05). (H) A 2-way ANOVA revealed a trend 
towards a ChR2 effect (F1,38=3.606, P = 0.06) and interaction between ChR2 and drug 
(F1,38=3.097, P = 0.08) on amount of time spent in the center of the open field. Based on the 
previous findings, our planned comparisons revealed a significant increase amount of time 
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spent in the center of the open field of ChR2-Saline mice as compared to eYFP-Saline mice 
(t17=3.034, P < 0.01) and ChR2-U50 mice as compared to ChR2-Saline mice (t18=2.178, P 
< 0.05), indicating that though ChR2 activation of BLA-BNST neurons produced an 
anxiolytic effect, this was blocked by the KOR agonist U50,488. In addition, changes in 
locomotor behavior were seen in ChR2-U50 and eYFP-U50 mice (data not shown). A 2-way 
ANOVA revealed a significant effect of U50,488 treatment on overall activity (F1,30=53.91, 
P < 0.0001). Tukey's post hoc tests showed that eYFP-U50 mice showed significantly 
decreased overall locomotor activity as compared to eYFP-saline mice (P < 0.05). Similarly, 
as expected, ChR2-U50 mice showed significant decreased overall locomotor as compared 
to ChR2-saline controls (P < 0.05). (I) Representative heatmaps for all groups. Scale bar 
indicates intensity of behavior.
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Figure 4. Optogenetic activation of BNST Dynorphin neurons inhibits eEPSCs in nonChR2 
expressing neurons, and KORs preferentially inhibit glutamate release onto DYN+ neurons
(A) Localization of DYN+ neurons in the BNST. DYN+ cells were found throughout the 
dorsal BNST in a Dyn-L10-EGFP reporter mouse. (B) Left, local dynorphin cells showed 
reliable light evoked action potentials at 20 hz. These cells synapsed locally, producing a 
light-evoked IPSC of approximately 423 pA, but no light-evoked EPSC. (C) 5 hz stimulation 
of DYN+ neurons produced a significant transient change in eEPSC amplitude (paired t-test, 
baseline v. min. 5-8, t4 = 6.033, P < 0.05), which returned to baseline (paired t-test, baseline 
v. min 11-15, t4 = 2.474, P > 0.05). (D) 20 hz stimulation of local DYN+ neurons produces a 
significant and lasting inhibition of eEPSC (paired t-test, baseline v. min 11-15, t4 = 10.42, P 
< 0.001). This effect is partially blocked by norBNI (unpaired t-test acsf v. norBNI block, 
min 16-20, t8 = 10.59, P < 0.0001). (E) 20 hz optogenetic stimulation of PVN to BNST 
DYN+ neurons produces a significant inhibition of eEPSC (paired t-test, baseline v. min 
11-15, t4 = 8.566, P < 0.001) but this was not significantly different from the inhibition seen 
when in the presence of the KOR antagonist norBNI (unpaired t-test, acsf+picrotoxin v. acsf
+picrotoxin+norBNI, t8 = 1.191, P > 0.1). (F) Mice were injected with a cre-inducible 
mCherry (AAV5-EF1α-DIO-mCherry) to the BNST, and ChR2 (AAV2-CaMKIIα-ChR2-
EYFP) to the BLA. Optogenetic activation of BLA-BNST DYN+ and DYN- neurons was 
then assessed. (G) Application of the KOR agonist U69,593 significantly reduced the BLA-
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BNST eEPSC amplitude onto both DYN+ (paired t-test, baseline v. min 21-25, t4 = 12.14, P 
< 0.001) and DYN- neurons (paired t-test, baseline v. min 21-25, t4 = 9.039, P < 0.001). 
However, the effect of KOR-mediated inhibition was significantly larger on DYN+ neurons 
as compared to DYN- neurons (unpaired t-test, DYN+ min 21-25 v. DYN- 21-25, t8 = 7.071, 
P < 0.001), indicating KOR activation in the BNST may preferentially inhibit BLA-DYN+ 
neurons. See also Supplemental Figures 1 and 2.
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